Targeting CD19 on B cells is a worthwhile strategy for treating unresponsive lymphomas, despite eliminating both cancerous and normal B cells.

“and the the poster child for this of course is cd19 and as you said every B cell is walking around with this marker on it just we don't have to get into why it's called cd19 and when a subset of B Cells Go on to become lymphoma that is otherwise unresponsive to other treatments lo and behold you could you know wipe out you could basically send in someone that's going to Target every cd19 — and and you'll get rid of the bad guys you'll get rid of some good guys and on balance it's it's worth it for sure”